Thursday, November 6, 2024The other long-expected big news item for market participants this week comes this afternoon, with the Federal Open Market Committee (FOMC) determining a new Fed funds rate. This follows the “red wave” election on Tuesday that still shows stock market indexes going higher after a gangbusters market Wednesday. Both the Dow and the Nasdaq are +80 points at this hour, with the S&P 500 up +15 points. New Jobless Claims Stay Tame; Longer-Term Claims HigherThis being Thursday morning, we ...

CHINA - 2024/10/13: In this illustration, the Moderna logo is displayed on the screen of an iPad. ... [+] (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty ImagesThe stock price of Moderna has seen a sharp 48% fall this year. From its lows of around $50, it is expected to see a rebound after posting a solid Q3 beat. The company reported revenue of $1.86 billion and adjusted earnings of $0.03 per share, compared to the consensus estimates of $1.2 ...

On Thursday, Moderna Inc MRNA stock is trading higher after the company reported better-than-expected third-quarter sales.Moderna reported third-quarter revenue of $1.83 billion, compared with $1.83 billion a year earlier, beating the consensus of $1.25 billion.The company attributed the growth to higher sales in the U.S. market following the earlier launch of the updated COVID-19 vaccine.With FDA approval granted three weeks earlier than in the previous year, the company was able to meet demand more effect ...

Third Quarter 2024 Financial Results November 7, 2024 mode © 2024 Moderna, Inc. All rights reserved. Forward-looking statements and disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: Moderna's expected product sales in 2024 and trends informing Moderna's 2024 sales outlook; Moderna's ability to drive vaccination rates; Moderna's expectations regarding the 2025/2026 contractin ...

Moderna (MRNA) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $1.89 per share. This compares to loss of $1.39 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 101.59%. A quarter ago, it was expected that this biotechnology company would post a loss of $3.47 per share when it actually produced a loss of $3.33, delivering a surprise of 4.03%.Over the last four quarters, the ...

Moderna on Thursday posted a surprise profit for the third quarter, smashing Wall Street estimates, as its cost-cutting efforts took hold and sales of its Covid vaccine came in higher than expected. The biotech company posted a net income of $13 million, or 3 cents per share, for the third quarter. That compares with a net loss of $3.63 billion, or $9.53 cents per share, reported for the year-ago period.Moderna is slashing expenses, with a recently announced goal of achieving $1.1 billion in savings by 2027 ...

Exhibit 99.1 Moderna Reports Third Quarter 2024 Financial Results and Provides Business Updates Reports third quarter revenues of $1.9 billion, GAAP net income of $13 million and GAAP EPS of $0.03 Achieves year-to-date product sales of $2.2 billion; reiterates 2024 expected product sales of $3.0 to $3.5 billion Initiated dosing in two pivotal Phase 3 trials to assess efficacy of investigational mRNA vaccines against norovirus and influenza Announces expansion of its Executive Committee CAMBRIDGE, MA / ACCES ...

Moderna, Inc. MRNA will release earnings results for its third quarter, before the opening bell on Thursday, Nov. 7.Analysts expect the Cambridge, Massachusetts-based company to report a quarterly loss at $1.9 per share, versus a year-ago loss of $9.53 per share. Moderna projects to report revenue of $1.25 billion for the quarter, compared to $1.83 billion a year earlier, according to data from Benzinga Pro.On Oct. 28, On Monday, Merck & Co Inc MRK and Moderna announced the initiation of INTerpath-009, a pi ...

Moderna (MRNA) is set to report third-quarter 2024 earnings on Nov. 7, before the opening bell. The Zacks Consensus Estimate for sales and earnings is pegged at $1.25 billion and a loss of $1.91 per share, respectively. Both metrics indicate a significant decline from the year-ago levels.Estimates for Moderna’s 2024 loss per share have increased from $9.52 to $9.88 in the past 60 days. During the same period, estimates for 2025 loss per share have risen from $7.37 to $8.59. Image Source: Zacks Investment Re ...

Moderna (MRNA) closed the latest trading day at $55.22, indicating a +0.77% change from the previous session's end. This change outpaced the S&P 500's 0.16% gain on the day. Meanwhile, the Dow experienced a drop of 0.37%, and the technology-dominated Nasdaq saw an increase of 0.78%. Prior to today's trading, shares of the biotechnology company had lost 18% over the past month. This has lagged the Medical sector's loss of 4.09% and the S&P 500's gain of 1.67% in that time. Investors will be eagerly watching ...